Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Laura Ghezzi, Elio Scarpini & Daniela Galimberti. (2013) Disease-modifying drugs in Alzheimer’s disease. Drug Design, Development and Therapy 7, pages 1471-1479.
Read now
Read now
María Teresa amboage-paz & José Antonio díaz-peromingo. (2008) Effect of risperidone on serum lipids and cerebrovascular mortality among elderly dementia patients with associated behavioral disturbances. International Journal of Psychiatry in Clinical Practice 12:3, pages 196-201.
Read now
Read now
Vincent Mok, Adrian Wong, Simon Ho, Thomas Leung, Wynnie WM Lam & Ka Sing Wong. (2007) Rivastigmine in Chinese patients with subcortical vascular dementia. Neuropsychiatric Disease and Treatment 3:6, pages 943-948.
Read now
Read now
Abhilash K Desai & George T Grossberg. (2005) Rivastigmine for Alzheimer’s disease. Expert Review of Neurotherapeutics 5:5, pages 563-580.
Read now
Read now
Renu Agrawal. (2005) Probiotics: An emerging food supplement with health benefits. Food Biotechnology 19:3, pages 227-246.
Read now
Read now
Articles from other publishers (37)
Shu-Wen Cheng, Chao-Wei Lu, Hung-Yu Chan, Jiahn-Jyh Chen & Chun-Chi Hsu. (2022) Antipsychotic prescription patterns and associated factors among the elderly with psychiatric illnesses. International Clinical Psychopharmacology 37:4, pages 151-158.
Crossref
Crossref
Immacolata Vecchio, Luca Sorrentino, Annamaria Paoletti, Rosario Marra & Mariamena Arbitrio. (2021) The State of The Art on Acetylcholinesterase Inhibitors in the Treatment of Alzheimer’s Disease. Journal of Central Nervous System Disease 13, pages 117957352110291.
Crossref
Crossref
Nages Nagaratnam & Kujan Nagaratnam. 2019. Advanced Age Geriatric Care. Advanced Age Geriatric Care
305
311
.
Alexander Wolf, Stefan Leucht & Frank-Gerald Pajonk. (2016) Do antipsychotics lead to cognitive impairment in dementia? A meta-analysis of randomised placebo-controlled trials. European Archives of Psychiatry and Clinical Neuroscience 267:3, pages 187-198.
Crossref
Crossref
. 2015. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
229
415
.
André Smith, Karen Kobayashi, Neena Chappell & Dann Hoxsey. (2011) The controversial promises of cholinesterase inhibitors for Alzheimer's disease and related dementias: A qualitative study of caregivers' experiences. Journal of Aging Studies 25:4, pages 397-406.
Crossref
Crossref
Teus van Laar, Peter Paul De Deyn, Dag Aarsland, Paolo Barone & James E Galvin. (2011) Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. CNS Neuroscience & Therapeutics 17:5, pages 428-441.
Crossref
Crossref
Klaus Seppi, Daniel Weintraub, Miguel Coelho, Santiago Perez-Lloret, Susan H. Fox, Regina Katzenschlager, Eva-Maria Hametner, Werner Poewe, Olivier Rascol, Christopher G. Goetz & Cristina Sampaio. (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders 26:S3, pages S42-S80.
Crossref
Crossref
Paul Howard, Robert Twycross, John Shuster, Mary Mihalyo & Andrew Wilcock. (2011) Antipsychotics. Journal of Pain and Symptom Management 41:5, pages 956-965.
Crossref
Crossref
F. Caraci, G. Molinaro, G. Battaglia, M. L. Giuffrida, B. Riozzi, A. Traficante, V. Bruno, M. Cannella, S. Merlo, X. Wang, B. A. Heinz, E. S. Nisenbaum, T. C. Britton, F. Drago, M. A. Sortino, A. Copani & F. Nicoletti. (2010) Targeting Group II Metabotropic Glutamate (mGlu) Receptors for the Treatment of Psychosis Associated with Alzheimer's Disease: Selective Activation of mGlu2 Receptors Amplifies -Amyloid Toxicity in Cultured Neurons, Whereas Dual Activation of mGlu2 and mGlu3 Receptors Is Neuroprotective. Molecular Pharmacology 79:3, pages 618-626.
Crossref
Crossref
Nils Erik Gilhus, Michael P. Barnes & Michael BraininW. H. Oertel, A. Berardelli, B. R. Bloem, U. Bonuccelli, D. Burn, G. Deuschl, E. Dietrichs, G. Fabbrini, J. J. Ferreira, A. Friedman, P. Kanovsky, V. Kostic, A. Nieuwboer, P. Odin, W. Poewe, O. Rascol, C. Sampaio, M. Schüpbach, E. Tolosa & C. Trenkwalder. 2010. European Handbook of Neurological Management. European Handbook of Neurological Management
237
267
.
Salvatore Gentile. (2010) Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology 212:2, pages 119-129.
Crossref
Crossref
Karen Van Leuven. (2010) Psychotropic Medications and Falls in Older Adults. Journal of Psychosocial Nursing and Mental Health Services 48:9, pages 35-43.
Crossref
Crossref
J. Lindesay, R. Bullock, H. Daniels, M. Emre, H. Förstl, L. Frölich, T. Gabryelewicz, P. Martínez-Lage, A. U. Monsch, M. Tsolaki & T. van Laar. (2010) Turning principles into practice in Alzheimer’s disease. International Journal of Clinical Practice 64:9, pages 1198-1209.
Crossref
Crossref
David G Le Couteur, Gary A Ford & Andrew J McLachlan. (2010) Evidence, Ethics and Medication Management in Older People. Journal of Pharmacy Practice and Research 40:2, pages 148-152.
Crossref
Crossref
David G. Le Couteur, Hal Kendig, Vasi Naganathan & Andrew J. McLachlan. 2010. Medication Management in Older Adults. Medication Management in Older Adults
29
42
.
Mehrul Hasnain, W. Victor R. Vieweg, Mark S. Baron, Mary Beatty-Brooks, Antony Fernandez & Anand K. Pandurangi. (2009) Pharmacological Management of Psychosis in Elderly Patients with Parkinsonism. The American Journal of Medicine 122:7, pages 614-622.
Crossref
Crossref
Annette Leibing. (2009) Tense Prescriptions? Alzheimer Medications and the Anthropology of Uncertainty. Transcultural Psychiatry 46:1, pages 180-206.
Crossref
Crossref
Marie-Odile Krebs. (2008) Développement d’un antipsychotique : nouvelles directions. Therapies 63:3, pages 257-262.
Crossref
Crossref
F. Nourhashemi, S. Gillette-Guyonnet, S. Andrieu, Y. Rolland, P. -J. Ousset & B. Vellas. (2008) A randomized trial of the impact of a specific care plan in 1120 Alzheimer’s patients (PLASA study) over a two-year period: Design and baseline data. The Journal of Nutrition Health and Aging 12:4, pages 263-271.
Crossref
Crossref
Patrick J. Barry, Paul Gallagher & Cristin Ryan. (2008) Inappropriate prescribing in geriatric patients. Current Psychiatry Reports 10:1, pages 37-43.
Crossref
Crossref
M. Rainer, M. Haushofer, H. Pfolz, C. Struhal & W. Wick. (2007) Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: Efficacy, safety and cognitive function. European Psychiatry 22:6, pages 395-403.
Crossref
Crossref
Ilya Lipkovich, Jonna Ahl, Russell Nichols, Thomas Hardy & Vicki Poole Hoffmann. (2016) Weight Changes During Treatment With Olanzapine in Older Adult Patients With Dementia and Behavioral Disturbances. Journal of Geriatric Psychiatry and Neurology 20:2, pages 107-114.
Crossref
Crossref
Claire Biernacki. 2007. Dementia: Metamorphosis in Care. Dementia: Metamorphosis in Care
189
200
.
Barbara J. Zarowitz, Richard Stefanacci, Kelly Hollenack, Terry O?Shea, Joseph Gruber & Eric G. Tangalos. (2007) The Application of Evidence-Based Principles of Care in Older Persons (Issue 5): Alzheimer?s Disease. Journal of the American Medical Directors Association 8:3, pages 183-193.
Crossref
Crossref
Bhaskara P. Shelley & Jaber Al Khabouri. (2007) The Spectrum of Dementia: Frequency, Causes and Clinical Profile. Dementia and Geriatric Cognitive Disorders 24:4, pages 280-287.
Crossref
Crossref
Markus Müller. (2006) Grenzen der ökonomischen Bewertung von Arzneimitteln aus klinischpharmakologischer SichtLimitations of pharmacoeconomics from a clinical-pharmacological point of view. Wiener Medizinische Wochenschrift 156:23-24, pages 619-621.
Crossref
Crossref
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol & C. Sampaio. (2006) Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. European Journal of Neurology 13:11, pages 1186-1202.
Crossref
Crossref
Elisabetta Farina, Federica Mantovani, Raffaella Fioravanti, Gerardo Rotella, Fabiana Villanelli, Emilia Imbornone, Fabrizio Olivotto, Morena Tincani, Margherita Alberoni, Emilia Petrone, Raffaello Nemni & Alfredo Postiglione. (2006) Efficacy of Recreational and Occupational Activities Associated to Psychologic Support in Mild to Moderate Alzheimer Disease. Alzheimer Disease & Associated Disorders 20:4, pages 275-282.
Crossref
Crossref
M. Mauri, A. Mancioli, V. Rebecchi, S. Corbetta, C. Colombo & G. Bono. (2006) Amisulpride in the treatment of behavioural disturbances among patients with moderate to severe Alzheimer's disease. Acta Neurologica Scandinavica 114:2, pages 97-101.
Crossref
Crossref
Mervat N. Kozman, John Wattis & Stephen Curran. (2006) Pharmacological management of behavioural and psychological disturbance in dementia. Human Psychopharmacology: Clinical and Experimental 21:1, pages 1-12.
Crossref
Crossref
M. Horstink, E. Tolosa, U. Bonuccelli, G. Deuschl, A. Friedman, P. Kanovsky, J. P. Larsen, A. Lees, W. Oertel, W. Poewe, O. Rascol & C. Sampaio. 2006. European Handbook of Neurological Management. European Handbook of Neurological Management
245
265
.
Ann M Mortimer, Charles J Shepherd, Michael Rymer & Alison Burrows. (2005) Primary care use of antipsychotic drugs: an audit and intervention study. Annals of General Psychiatry 4:1.
Crossref
Crossref
Daniel Weintraub & Ira R. Katz. (2005) Pharmacologic Interventions for Psychosis and Agitation in Neurodegenerative Diseases: Evidence About Efficacy and Safety. Psychiatric Clinics of North America 28:4, pages 941-983.
Crossref
Crossref
Jeffrey L. Cummings. (2014) Behavioral and Neuropsychiatric Outcomes in Alzheimer's Disease. CNS Spectrums 10:S18, pages 22-25.
Crossref
Crossref
Michael F. O'Neill. (2005) Difficult times for Alzheimer's treatments. Drug Discovery Today 10:20, pages 1333-1335.
Crossref
Crossref
. (2005) Current awareness in geriatric psychiatry. International Journal of Geriatric Psychiatry 20:8, pages 801-808.
Crossref
Crossref